"any other company with this news would have been up $ 2+"

Not any other biotech under similar circumstances. ASCO is normally a sell the news type of event for most biotechs. When it was announced that the T-DM1 trial would have to continue for more events, it was a no-brainer that the stock would sell off--very elementary biotech investing 101. IMGN is over-valued at $15 pre-approval as shown by any reasonable discounted cash flow projection. I realize you are just talking your book as usual but your post was hogwash.

"It is now IMO obvious that IMGN is not going to move up and stay up even if the drug gets approved."

IMGN's price will trend up when a PDUFA date is eventually set. It will easily be at least $5 higher or more from the current price on the post-approval spike. To state that the price will not move up on approval is really a stupid comment even if you are talking your book.